Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 --0%
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.24), $0.08 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $16.31 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Banks Collaborate on Principles for Trusted Agentic Commerce
- Tustin Cosmetic Dentist, OC Graceful Smiles, Expands Sedation Dentistry Program for Patients With Dental Anxiety
- Sebastian HVAC Contractors, Air Docs Heating & Cooling, Launch "Oldest AC Contest"
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
